Merck Exceeds Revenue Expectations Despite $4.2B Loss in Q1 2026

Merck Delivers Strong Q1 Performance Amid Major Acquisition Costs

Pharmaceutical giant Merck & Co. (MRK) delivered quarterly results that surpassed Wall Street expectations on Thursday, despite posting a substantial net loss due to acquisition-related charges. The company's robust performance was primarily driven by continued momentum in its blockbuster cancer immunotherapy franchise.

Revenue Growth Outpaces Analyst Projections

The New Jersey-based drugmaker generated $16.29 billion in first-quarter revenue, representing a solid 5% increase from the corresponding period in 2025. This figure exceeded analyst consensus estimates of $15.82 billion, according to CNBC data, demonstrating the company's ability to maintain growth momentum in a competitive pharmaceutical landscape.

Keytruda Continues Stellar Performance Trajectory

Merck's crown jewel, the cancer immunotherapy Keytruda, delivered exceptional results with quarterly sales reaching $8.03 billion—a robust 12% year-over-year expansion. The drug's performance was bolstered by strong demand across multiple cancer treatment scenarios, particularly in advanced metastatic cases.

Notably, physicians increasingly prescribed Keytruda for earlier-stage malignancies, including triple-negative breast cancer, cervical cancer, and renal cell carcinoma. The newly launched subcutaneous version, branded as Keytruda Qlex, contributed $128 million to overall sales during its first full quarter of commercial availability.

Acquisition Charges Drive Significant Net Loss

Despite strong operational performance, Merck reported a net loss of $4.24 billion, equivalent to $1.72 per share, marking a dramatic shift from the $5.08 billion profit ($2.01 per share) recorded in Q1 2025. This substantial loss primarily resulted from a $3.62 per share charge associated with the Cidara Therapeutics acquisition.

When excluding acquisition-related expenses and other one-time items, the company posted an adjusted loss of $1.28 per share, which was notably better than analyst expectations of a $1.51 per share loss.

Mixed Results Across Product Portfolio

Winrevair, Merck's treatment for a rare and fatal lung condition, demonstrated impressive commercial traction with $525 million in quarterly sales—an 88% surge compared to the previous year. The drug's expansion was fueled by increased adoption among American patients and successful launches in Japanese and European markets.

However, not all products shared this success. Gardasil, the company's HPV vaccine, experienced a 19% decline in revenue to $1.07 billion. This decrease reflected ongoing challenges in China, where Merck had previously halted shipments, along with reduced volumes in Japan and the United States.

The diabetes medication portfolio, including Januvia and Janumet, faced significant headwinds with combined revenues falling 28% to $574 million. This decline stemmed from pricing pressures and weakening domestic demand, compounded by generic competition in international markets.

Animal Health Division Shows Strong Growth

Merck's animal health segment provided a bright spot with revenues of $1.79 billion, marking a 13% year-over-year increase. Growth was broad-based across both livestock and companion animal product lines, reflecting the division's diversified strength.

Updated Financial Guidance Reflects Confidence

Looking toward the remainder of 2026, Merck refined its full-year revenue projections to a range of $65.8 billion to $67 billion, raising the lower bound from the previously stated $65.5 billion. The company also adjusted its earnings per share guidance to $5.04-$5.16, slightly above the earlier $5.00-$5.15 range.

These projections incorporate the Cidara acquisition charge but exclude the anticipated impact of the pending Terns Pharmaceuticals acquisition, expected to close in May. Management indicated this transaction will result in an additional one-time charge of approximately $2.35 per share.

Market Implications and Future Outlook

Merck's results underscore the pharmaceutical industry's ongoing consolidation trend and the critical importance of innovation-driven growth. The company's ability to exceed revenue expectations while managing significant acquisition costs demonstrates operational resilience and strategic focus on high-value therapeutic areas.